Skip to content

Construction and Efficacy Analysis of a Metabolomics-Based Risk Assessment System for Recurrent Urolithiasis: A Single-Center Prospective Study

Construction and Efficacy Analysis of a Metabolomics-Based Risk Assessment System for Recurrent Urolithiasis: A Single-Center Prospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123479
Enrollment
Unknown
Registered
2026-04-27
Start date
2026-05-06
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney stone

Interventions

Observation group:None

Sponsors

The Eighth Affiliated Hospital of Sun Yat-sen University (Futian District, Shenzhen)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Eligibility criteria: (1) Radiologically confirmed urolithiasis; (2) Age 18–80 years; (3) Stone-free status documented by ultrasound and KUB at 1-month post-treatment; (4) Signed informed consent. All of the above criteria must be met simultaneously to be included.

Exclusion criteria

Exclusion criteria: (1) Age 80 years; (2) Pregnant or lactating women; (3) Failure to achieve complete stone clearance after treatment; (4) Presence of urinary tract malformation or urinary obstruction not caused by stones; (5) Participation in other clinical trials within three months. Those who meet any of the above criteria will not be included.

Design outcomes

Primary

MeasureTime frame
Oxalic acid;Uric Acid;Phosphoric acid; Sulfuric acid;Cystine;Urine volume;

Secondary

MeasureTime frame
Magnesium;Calcium;Sodium;Chlorine;Potassium;Creatinine;Urea;

Countries

China

Contacts

Public ContactZhaohui He

The Eighth Affiliated Hospital of Sun Yat-sen University (Futian District, Shenzhen)

hechh9@mail.sysu.edu.cn+86 139 2275 3190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026